Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FibroGen Appoints Suzanne Blaug to Board of Directors

GlobeNewswire June 5, 2019

FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm

Press Releases May 15, 2019

FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm

GlobeNewswire May 10, 2019

FibroGen Reports First Quarter 2019 Financial Results

GlobeNewswire May 9, 2019

FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program

GlobeNewswire May 9, 2019

FibroGen to Report First Quarter 2019 Financial Results

GlobeNewswire May 6, 2019

FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire April 15, 2019

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire February 27, 2019

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire February 22, 2019

Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire January 17, 2019

FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease

GlobeNewswire December 20, 2018

FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

GlobeNewswire December 17, 2018

FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

GlobeNewswire December 6, 2018

New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 27, 2018

FibroGen Reports Third Quarter 2018 Financial Results

GlobeNewswire November 8, 2018

FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018

GlobeNewswire November 2, 2018

ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

GlobeNewswire October 30, 2018

FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting

GlobeNewswire October 25, 2018

FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting

GlobeNewswire October 16, 2018

Research Report Identifies The Habit Restaurants, Datawatch, SMART SAND INC, Independence Contract Drilling, Pareteum, and FibroGen with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire October 16, 2018